EA201301308A1 - COMBINATION FOR THE TREATMENT OF DIABETES MELLITUS - Google Patents

COMBINATION FOR THE TREATMENT OF DIABETES MELLITUS

Info

Publication number
EA201301308A1
EA201301308A1 EA201301308A EA201301308A EA201301308A1 EA 201301308 A1 EA201301308 A1 EA 201301308A1 EA 201301308 A EA201301308 A EA 201301308A EA 201301308 A EA201301308 A EA 201301308A EA 201301308 A1 EA201301308 A1 EA 201301308A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
treatment
diabetes mellitus
dissociating
sugar
Prior art date
Application number
EA201301308A
Other languages
Russian (ru)
Other versions
EA028394B1 (en
Inventor
Сергей Юрьевич Лешков
Нина Сергеевна Вихриева
Сергей Петрович Кречетов
Original Assignee
Сергей Юрьевич Лешков
Нина Сергеевна Вихриева
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сергей Юрьевич Лешков, Нина Сергеевна Вихриева filed Critical Сергей Юрьевич Лешков
Publication of EA201301308A1 publication Critical patent/EA201301308A1/en
Publication of EA028394B1 publication Critical patent/EA028394B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Предложена комбинация для лечения сахарного диабета, которая может быть выполнена в виде фармацевтической композиции или фармацевтического набора. Комбинация содержит сахароснижающие средства и природные фенольные соединения, способные к разобщению окислительного фосфорилирования. Такая комбинация позволяет снизить возможность появления побочных эффектов от применения сахароснижающих препаратов и, в частности, риск развития лактатного ацидоза.A combination is proposed for the treatment of diabetes mellitus, which may be in the form of a pharmaceutical composition or pharmaceutical kit. The combination contains hypoglycemic agents and natural phenolic compounds capable of dissociating oxidative phosphorylation. This combination allows you to reduce the possibility of side effects from the use of sugar-lowering drugs and, in particular, the risk of lactic acidosis.

EA201301308A 2011-06-02 2012-04-05 Combination for treatment of diabetes mellitus EA028394B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011122374/15A RU2451506C1 (en) 2011-06-02 2011-06-02 Combination for treatment of diabetes and complications thereof
PCT/RU2012/000254 WO2012166008A1 (en) 2011-06-02 2012-04-05 Combination for treatment of diabetes mellitus

Publications (2)

Publication Number Publication Date
EA201301308A1 true EA201301308A1 (en) 2014-03-31
EA028394B1 EA028394B1 (en) 2017-11-30

Family

ID=46231593

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301308A EA028394B1 (en) 2011-06-02 2012-04-05 Combination for treatment of diabetes mellitus

Country Status (7)

Country Link
EP (1) EP2714022A1 (en)
JP (1) JP2014527506A (en)
KR (1) KR101567660B1 (en)
CN (1) CN103402506A (en)
EA (1) EA028394B1 (en)
RU (1) RU2451506C1 (en)
WO (1) WO2012166008A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548731C2 (en) * 2012-10-24 2015-04-20 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" Medication and method of complex therapy of patients with diabetes mellitus
CN105263484B (en) * 2013-05-24 2018-08-03 株式会社加龄.营养研究所 Including the pharmaceutical composition of melbine and dihydroquercetin and its purposes for treating cancer
US10442610B2 (en) 2014-03-11 2019-10-15 Starbucks Corporation Pod-based restrictors and methods
CN105902761A (en) * 2016-06-16 2016-08-31 河南中医学院 Application of flos sophorae powder in preparing drugs for treating hyperglycemia and diabetes
FR3062795B1 (en) * 2017-02-16 2019-06-07 Valbiotis PHARMACEUTICAL ACTIVE INGREDIENT AND USE IN PARTICULAR IN THE PREVENTION AND TREATMENT OF METABOLIC DERGLEMENTS IN MAN AND ANIMAL.
RU2687256C1 (en) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Method of personalized treatment of chronic renal disease in patients with diabetic nephropathy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027982A1 (en) * 1996-12-24 1998-07-02 Sumitomo Pharmaceuticals Co., Ltd. Composition containing ascorbic acid
SI0974356T1 (en) 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
KR20000019716A (en) * 1998-09-15 2000-04-15 박호군 Composition comprising bioflavonoid compounds for descending blood sugar
ITMI20002019A1 (en) 1999-09-17 2002-03-15 Novartis Ag METHOD FOR THE TREATMENT OF METABOLIC DISORDERS, IN PARTICULAR DIABETES OR A DISEASE OR A CONDITION ASSOCIATED WITH DIABETES
JP4719372B2 (en) * 2000-06-21 2011-07-06 花王株式会社 PPAR-dependent gene transcription activator
AU2001276682A1 (en) * 2000-08-01 2002-02-13 Oryza Oil and Fat Chemical Co., ltd. Sugar absorption inhibitors and process for producing the same
JP2003300904A (en) * 2002-04-05 2003-10-21 National Cardiovascular Center Medicinal composition for suppressing progress of circulatory disturbance
KR20060121887A (en) * 2003-09-23 2006-11-29 디에스엠 아이피 어셋츠 비.브이. Compositions for the treatment and prevention of diabetes mellitus
MXPA06003838A (en) * 2003-10-10 2006-07-03 Resverlogix Corp Treatment of diseases associated with the egr-1 enhancer element.
RU2284829C2 (en) * 2004-12-16 2006-10-10 Пятигорская государственная фармацевтическая академия Antidiabetic species
CA2596311A1 (en) * 2005-01-20 2006-07-27 Stephen Holt Herbal compositions containing hoodia
EP1905450A1 (en) * 2005-07-12 2008-04-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar gamma agonist
JP5246833B2 (en) * 2005-12-16 2013-07-24 独立行政法人産業技術総合研究所 Adiponectin production enhancer
JP5246834B2 (en) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 Adiponectin production enhancer
CN101176786A (en) * 2006-11-08 2008-05-14 中国科学院上海生命科学研究院 Method and composition for increasing insulin sensibility
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
TW200903710A (en) 2007-07-11 2009-01-16 Promos Technologies Inc Manufacturing method for shallow trench isolation
US20090175973A1 (en) * 2007-09-05 2009-07-09 Nina Vikhrieva Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders
CN101250106B (en) * 2008-03-27 2011-05-18 北京市农林科学院 Method for extracting chlorogenic acid
JP5054594B2 (en) * 2008-03-31 2012-10-24 花王株式会社 Lipid metabolism improver
RU2378003C1 (en) * 2008-06-06 2010-01-10 Сергей Юрьевич Лешков Pharmaceutical composition based on green coffee berry extract, method for making and applying
AU2009307753A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
WO2010089874A1 (en) * 2009-02-05 2010-08-12 フジッコ株式会社 Ppar-γ-expression-enhancing agent, adiponectin-production-enhancing agent, ucp-activating agent, and pharmaceutical preparation, food or beverage comprising any one of the agents
PL2418965T3 (en) * 2009-04-17 2016-12-30 Hydroxytyrosol combinations for enhancing mitochondrial function and energy production.
WO2010134085A1 (en) * 2009-05-20 2010-11-25 Institute Of Life Sciences Pharmaceutical co-crystals of quercetin
JP2011063557A (en) * 2009-09-18 2011-03-31 Lion Corp Ppar activator
ES2356536B1 (en) * 2009-09-23 2012-02-13 Probelte Pharma, Sa A composition used as a prebiotic that contains a pomegranate extract and a food that includes said composition.
CN101851221B (en) * 2010-05-27 2012-09-05 东北林业大学 Method for preparing dihydroquercetin from larches

Also Published As

Publication number Publication date
EA028394B1 (en) 2017-11-30
KR101567660B1 (en) 2015-11-10
WO2012166008A1 (en) 2012-12-06
JP2014527506A (en) 2014-10-16
RU2451506C1 (en) 2012-05-27
KR20140008452A (en) 2014-01-21
CN103402506A (en) 2013-11-20
EP2714022A1 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
EA201301308A1 (en) COMBINATION FOR THE TREATMENT OF DIABETES MELLITUS
ECSP13012658A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HONEYFIBROSIS
GT201400136A (en) COMPOUNDS AND METHODS OF BENZALDEHYDE SUBSTITUTED FOR USE IN INCREASING OXYGENATION OF FABRICS
SV2011003901A (en) ARILO COMPOUNDS WITH HETEROCYCLIC SUBSTITUTES AS HIF INHIBITORS
EA201290919A1 (en) INDASOLIC COMPOUNDS AND THEIR APPLICATION
CL2008000198A1 (en) COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF SICK DISEASES AS TYPE 2 DIABETES, LIPID DISORDER, OBESITY AND ATEROSCLEROSIS.
UA113849C2 (en) THE APPLICATION OF SIGMA LIGANDS IN TYPE 2 PATIENTS WITH PAIN
BRPI0517701A8 (en) diabetes mellitus treatment methods
EA201391028A1 (en) HYPOLIPIDEMIC ANTI-DIABETIC MEANS
EA201500265A1 (en) ANTI-FLY VIRUS REPLICATION INHIBITORS
EA201300522A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
EA201491335A1 (en) BIGUANID COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISORDERS
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
MX2012006744A (en) Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases.
EA201201623A1 (en) TREATMENT OF DIABETES TYPE 2
EA201490103A1 (en) HYDROXYMETHYLARILILEDRAIN PYRROTHRIAZINES AS ALK1 INHIBITORS
EA201171339A1 (en) THE WAY TO REDUCE THE INTRA-GL PRESSURE IN PEOPLE
EA201000391A1 (en) Compound, representing itself an inhibitor of glycogenphosphorylase, and its pharmaceutical composition
MX349254B (en) Compounds for treatment of metabolic syndrome.
CO6592101A2 (en) Methods to treat diabetic foot ulcers
RS53826B1 (en) Composition comprising powdered eggshell membrane for use in treating diabetes mellitus
EA201000392A1 (en) Compound, representing itself an inhibitor of glycogenphosphorylase, and its pharmaceutical composition
DOP2010000400A (en) 7-SULFANILMETIL-, 7-SULFINILMETIL- AND 7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME
UA100883C2 (en) Use of dronedarone or one of its pharmaceutically acceptable salts for preparing a medicament for the treatment of patients with arrhythmia and an increased creatinine level due to dronedarone administration

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU